GlobeNewswire
-
Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola
16/11/2026 -
Carlsmed to Participate in Upcoming Investor Conferences
16/11/2026 -
Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results
16/11/2026 -
Daré Bioscience Reports Third Quarter 2026 Financial Results and Highlights Commercial Execution and Pipeline Advancement
16/11/2026 -
Windward Bio Announces Closing of $251.2 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16/11/2026 -
CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia
16/11/2026 -
EAACI connects allergy research with public action on anaphylaxis in Utrecht
16/11/2026 -
EAACI calls for allergy and respiratory health to be part of climate action at COP31
16/11/2026 -
RBC Foundation donates $1.3 million in Holland Bloorview to help fuel a more inclusive future for children and youth with disabilities and developmental differences
16/11/2026 -
Hoag is the First Hospital on the West Coast to Offer New, Groundbreaking Breast Imaging Technology to Patients
16/11/2026 -
Après la vigne et les légumes, Amoéba et Koppert étendent leur partenariat à l’arboriculture en Europe
16/11/2026 -
Following vineyards and vegetable crops, Amoéba and Koppert expand their partnership into orchards across Europe
16/11/2026 -
European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
16/11/2026 -
NewGen Provides Business Update
16/11/2026 -
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
16/11/2026 -
Former Cross Country Healthcare CEO Bill Grubbs Takes Expanded Role as LUKE Executive Chairman
16/11/2026 -
Dr. Robert Langer, Co-Founder of Moderna, Joins PolarityBio’s Board of Directors
16/11/2026 -
Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
16/11/2026 -
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
16/11/2026
Pages